Asher Bio

Asher Bio develops engineered IL2 therapies that selectively target CD8+ T cells to treat cancer while minimizing systemic toxicity.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series B
Initial Investment Year
2021
Asher Portco Hover Image